BRISTOL-MYERS SQUIBB QUESTRAN "ACTUAL USE" STUDIES NEEDED TO SUPPORT Rx-TO-OTC SWITCH, FDA CMTE. FINDS; CURRENT DATA DO NOT SUPPORT SWITCH PETITION
Actual use studies of Bristol-Myers Squibb's Questran are needed to provide data that could support an Rx-to-OTC switch for the cholesterol-lowering resin cholestyramine, members of FDA's Nonprescription Drugs and Endocrinologic & Metabolic Drugs Advisory Committees suggested at a Sept. 27 meeting in Rockville, Md.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth